Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia.

[1]  A. Taher,et al.  Cerebral infarction in β-thalassemia intermedia: breaking the silence. , 2012, Thrombosis research.

[2]  M. Cappellini,et al.  Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. , 2012, Blood cells, molecules & diseases.

[3]  Vip Viprakasit,et al.  Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. , 2012, Blood.

[4]  M. Cappellini,et al.  Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. , 2012, Blood reviews.

[5]  S. Rivella.  The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. , 2012, Blood reviews.

[6]  A. Taher,et al.  Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major , 2012, Annals of Hematology.

[7]  M. Cappellini,et al.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia , 2011, Haematologica.

[8]  A. Taher,et al.  Thrombosis in Thalassemia: Why are we so Concerned? , 2011, Hemoglobin.

[9]  A. Taher,et al.  Bone disease and skeletal complications in patients with β thalassemia major. , 2011, Bone.

[10]  M. Cappellini,et al.  Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. , 2010, Blood.

[11]  M. Cappellini,et al.  Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia , 2008, Haematologica.

[12]  D. Kell.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases , 2008, BMC Medical Genomics.

[13]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[14]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[15]  A. Hoffbrand,et al.  Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand , 2003, British journal of haematology.